Automated Multiplex Epigenome Histone Methylation Foundry Cap Rate 2026

Underwrite GMP Class A/B continuous synthetic dCas9-KRAB-MeCP2 epigenetic silencing and targeted H3K9me3 histone methyltransferase vector suites, $570/sqft base lease rates, and exit cap rates.

Underwriting Assumptions

Histone Cleanroom Footprint (sqft)

NNN Base Lease Rate ($/sqft/yr)

Turnkey GMP Histone Foundry Acquisition ($)

Target Exit Capitalization Rate (%)

Projected Economics

Net Operating Income (NOI)

Going-In Capitalization Rate

Stabilized Institutional Valuation